期刊文献+

组织工程复合皮肤应用于皮肤缺损创面的临床疗效观察 被引量:4

Clinical Effect Assessment of Tissue-engineered Composite Skin on the Donor Site Defect Wound
暂未订购
导出
摘要 目的:临床观察组织工程复合皮肤对烧伤整形后需植皮患者的供皮区缺损创面的有效性及安全性。方法:试验选取不同临床中心烧伤整形后需植皮患者,在供皮区部分创面作为试验区应用组织工程复合皮肤覆盖,邻近创面采用盐水纱布替代作为对照区,应用后按常规方法包扎固定。临床试验时间为6个月,治疗期间观察统计患者的创面反应,愈合时间及愈合情况;对组织工程复合皮肤改善创面愈合质量及安全性进行临床评估。根据创面试验组和对照组的创面愈合时间,应用SPSS统计软件对数据进行方差齐性检验,根据检验结果分别进行独立样本t或t’检验。结果:试验共收集有效病例19例。临床观察显示应用后试验区创面无明显免疫排斥及炎性反应,患者自述疼痛明显减轻,试验区创面愈合时间与对照区相比缩短8d,统计学分析有显著性差异。愈后随访部分患者试验区愈合质量好于对照区,应用后患者疼痛、瘢痕形成等不良反应明显减少。结论:结果表明组织工程复合皮肤作为活型皮肤替代物用于医源性皮肤缺损的修复,这为促进供皮区的创面愈合提供了切实可行的方法。 Objective: To investigate the clinical effect and safety of tissue engineered composite skin on the donor site wound, Method: Partial wound of patients from multi-clinical center were treated with tissue engineered composite skin, and the adjacent wound were treated with standard method as control site. The data including reaction of wound, healing time and cosmetic outcome were recorded during 6-month to explore the role of tissue engineered skin in improving the quality of regenerated skin. The difference of average healing time between experimental site and control site was analyzed with SPSS software. Results: In 19 effective cases, there were no obvious adverse events such as immunological rejection and inflammatory reaction on the wound when treated with TE skin. The average healing time of activskin treated wounds significantly decreased by about 8 day compared with the control site. The cosmetic outcome of regeneration skin was much better than the control site. Conclusion: These results suggested that activskin is a new bioactive skin substitute for the repair of skin defect. The application of tissue engineered composite skin has provided a practical and effective method to promote the healing of wound on the donor site.
出处 《现代生物医学进展》 CAS 2007年第12期1840-1842,F0003,共4页 Progress in Modern Biomedicine
基金 国家高技术发展计划(863计划)组织工程皮肤重大专项资助项目(2005AA205241) 陕西省科技攻关项目(2005k06-G6)
关键词 组织工程 皮肤 供皮区 创面 Tissue engineering Skin Donor site Wound
  • 相关文献

参考文献8

  • 1SUPP D M, KARPINSKIA C, BOYCE S T. Expression of human beta-defensins HBD-1, HBD-2, and HBD-3 in cultured keratinocytes and skin substitutes[J]. Bums, 2004,30:643-8
  • 2聂鑫,柴家科,肖厚安,王甲汉,张勇杰,秦瑞峰,金岩.组织工程活性皮肤用于皮肤慢性溃疡创面临床研究[J].生物医学工程与临床,2006,10(4):242-245. 被引量:12
  • 3VEVES A, FALANGA V. ARMSTRONG DG, et al. Graftskin, a Human Skin Equivalent, Is Effective in the Management of Nouinfected Neuropathic Diabetic Foot Ulcers [J]. Diabetes Care, 2001,24: 290-296
  • 4金岩,吕红兵,刘源,赵宇,聂鑫,刘晓亮,张勇杰.人全层组织工程皮肤的研制[J].实用口腔医学杂志,2002,18(2):163-166. 被引量:39
  • 5BELL E, EHRLICH HP, BUTTLE D J, et al. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness [J]. Science, 1981,211(4486):1052-1054
  • 6吕红兵,金岩,刘源,王新文,董蕊,刘晓亮,张勇杰,赵宇.生物活性皮肤替代物的超微结构观察[J].实用口腔医学杂志,2003,19(5):424-427. 被引量:6
  • 7VEVES A, AKBARI CM, PRIMAVERA J, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration [J]. Diabetes, 1998,47 ( 3 ) :457-463
  • 8刘晓亮,金岩,聂鑫,刘源,吕红兵,赵宇,王军琳,TipoeGL.同种异体组织工程复合皮肤移植修复大鼠皮肤缺损[J].第四军医大学学报,2002,23(11):980-982. 被引量:8

二级参考文献22

  • 1Auger FA,Pouliot R,Tremblay N,etal. Muhistep production of bioengineered skin substitutes: Sequential modulation of culture conditions. In Vitro Cell Dev Biol Anim,2000,36(2) :96.
  • 2Goulet F, Poitras A, Rouabhia M,et al. Stimulation of human keratinocyte proliferation through growth factor exchanges with dermal fibroblasts in vitro. Burns, 1996,22(2):107.
  • 3Bell E, Ehrlich HP,Buttle DJ ,et al. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science, 1981,211(4486) : 1052.
  • 4Gorelik Iu V, IYiakonov IA, K ukhareva LV, et al. Effects of extracellular matrix elements on pseudopodial activity of rat keratinocytes. Tsitologiia, 1998,40(12) : 1037.
  • 5Eaglstein WH, Falanga V. Tissue engineering and the development of Apligraf, A human skin equivalent. Clinieal Therapeuties, 1997,19(5 ) .. 894.
  • 6Beumer GJ,van Blitterswijk CA, Ponec M. Biocompatibility of a biodegradable matrix used as a skin substitute: An in vivo evaluation. J Biomed Mater Mater Res, 1994,28(5) :545.
  • 7Pham HT,Rosenblum BI,Lyons TE,et al.Evaluation of graftskin (Apligraf),a human skin equivalent,for the treatment of diabetic foot ulcers in a prospective,randomized,clinical trial[J].Wounds,1999,11:79-86.
  • 8Veves A,Akbari CM,Primavera J,et al.Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy,vascular disease,and foot ulceration[J].Diabetes,1998,47 (3):457-463.
  • 9Bell E,Ehrlich HP,Buttle DJ,et al.Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness[J].Science,1981,211 (4486):1052-1054.
  • 10Banta MN,Kirsner RS.Modulating diseased skin with tissue engineering:actinic purpura treated with Apligraf[J].Dermatol Surg,2002,28 (12):1103-1106.

共引文献51

同被引文献52

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部